Shionogi¡¯s experimental COVID-19 treatment Xocova won emergency approval in Japan, becoming the third oral treatment available in the country and the first to be developed locally.
Japan¡¯s health ministry authorized the emergency use of the therapy for COVID-19 patients 12 years old and older after a panel of experts recommended the treatment, Health Minister Katsunobu Kato told reporters at a briefing Tuesday. In September, Shionogi said patients given a low dose of Xocova saw their symptoms resolve 24 hours faster than those given a placebo in the late-stage study.
¡°Unlike oral drugs that have been approved so far, Xocova can be used among people with mild to moderate symptoms without risk factors,¡± said Kato. ¡°I expect it to contribute to fight against the coronavirus.¡±
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.